17 August 2026 | 7:36AM BST Equity Research Argenx SE (ARGX.BR): Myositis Phase 3 ALKIVIA readout a significant positive with DM representing upside As a reminder, as outlined at ARGX's July R&D event, in the ALKIVIA trial immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) were assessed as separate populations allowing for filing in one or both of the subtypes based on the data generated. As such, the positive IMNM data allows for a regulatory filing where the drug was awarded FDA breakthr ...